Claritev Corp

Claritev Corp(CTEV)の株式分析

$21.780

-1.594 (-7.32%)終値時点

Loading chart…
高値
24.510
始値
23.710
出来高加重平均価格
22.63
出来高
420.38K
時価総額
—
安値
21.600
売買代金
9.51M
EV/EBITDA(TTM)
8.58

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.

www.claritev.com

AI分析 of Claritev Corp (CTEV)

買い

Claritev Corporation (CTEV) appears to be a good buy right now. The current price is $23.50, which is significantly lower than the average analyst price target of $40, indicating a potential upside of over 70%. Additionally, the company has shown a positive trend with a 6.24% increase over the past five days and a narrowed quarterly loss of $59.23 million, down from $62.64 million year-over-year, reflecting improved operational efficiency. However, a key risk is the high debt-to-equity ratio, which stands at 0%, indicating potential financial instability if market conditions worsen.

バリュエーション指標

Claritev Corp(CTEV)の現在の予想PERは3.42で、5年平均は-0.65です。

予想PER

適正
5年平均 P/E
-0.65
現在のP/E
3.42
割高
3.43
割安
-4.74

予想EV/EBITDA

割安
5年平均 EV/EBITDA
9.23
現在のEV/EBITDA
8.58
割高
9.88
割安
8.58

予想PSR

適正
5年平均 P/S
0.58
現在のP/S
0.37
割高
0.84
割安
0.31

Alphio AI による CTEV の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%CTEV

$27.94

シナリオ価格

基

基本

基本 · 50%CTEV

$26.34

シナリオ価格

弱

弱気

弱気 · 25%CTEV

$21.83

シナリオ価格

CTEV を保有するクジラ

A

Ares Management LLC

+ を保有CTEV

-6.74%

3か月リターン

イベントタイムライン

2026-09-22 (ET)

09:30:00

Claritev Selected to Support World Trade Center Health Program

2026-09-15 (ET)

09:30:00

Claritev Appoints Ben Letham as Director

2026-08-07 (ET)

05:30:00

Company Raises FY26 Adjusted EBITDA Outlook to $620M

05:30:00

Claritev Q2 Revenue Reaches $257.48M, Exceeds Expectations

2026-07-14 (ET)

13:30:00

Justice Department Expands Antitrust Investigation into Claritev

ニュース

CTEV のよくある質問 — Alphio AI が回答

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors. It operates in the Industrials sector.

Claritev Corporation (CTEV) appears to be a good buy right now. The current price is $23.50, which is significantly lower than the average analyst price target of $40, indicating a potential upside of over 70%. Additionally, the company has shown a positive trend with a 6.24% increase over the past five days and a narrowed quarterly loss of $59.23 million, down from $62.64 million year-over-year, reflecting improved operational efficiency. However, a key risk is the high debt-to-equity ratio, which stands at 0%, indicating potential financial instability if market conditions worsen.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める